Business Context and Reporting Period
This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. on December 4, 2013. The filing discloses a corporate action regarding the declaration of a quarterly cash dividend on the Company's 6% Convertible Exchangeable Preferred Stock.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is the dividend amount.
- Dividend Declaration: $0.15 per share on 6% Convertible Exchangeable Preferred Stock.
- Record Date: January 17, 2014.
- Payment Date: February 3, 2014.
Material Changes
The filing reports the declaration of a dividend as a discrete event. It does not contain comparative financial data or material changes in operating results versus prior periods.
Guidance, Outlook, and Risks
Management noted that the Board considered financial analysis and surplus determinations before declaring the dividend. The filing explicitly states that while the Board will analyze future dividend declarations, there is no assurance that future quarterly dividends will be declared.
Investor Verification Checklist
- Verify the total number of outstanding shares of 6% Convertible Exchangeable Preferred Stock to calculate the total cash outflow for this dividend.
- Review the Company's most recent 10-K or 10-Q to assess the "surplus" and liquidity position mentioned by the Board.
- Confirm the payment date of February 3, 2014, for cash flow planning.